Drugs that contain Gabapentin Enacarbil
1. Horizant patents expiration
HORIZANT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8048917 | AZURITY | Prodrugs of GABA analogs, compositions and uses thereof |
Nov, 2022
(1 year, 5 months ago) | |
| US6818787 | AZURITY | Prodrugs of GABA analogs, compositions and uses thereof |
Apr, 2025
(11 months from now) | |
| US8026279 | AZURITY | Crystalline form of γ-aminobutyric acid analog |
Nov, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8686034 | AZURITY | Crystalline form of γ-aminobutyric acid analog |
Jan, 2025
(9 months from now) | |
| US8114909 | AZURITY | Treating or preventing restless legs syndrome using prodrugs of GABA analogs |
Apr, 2026
(1 year, 11 months from now) | |
| US8795725 | AZURITY | GABA analog prodrug sustained release oral dosage forms |
Jun, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jun 06, 2019 |
| Orphan Drug Exclusivity(ODE-25) | Jun 06, 2019 |
| New Chemical Entity Exclusivity(NCE) | Apr 06, 2016 |
| New Indication(I-652) | Jun 06, 2015 |
NCE-1 date: 07 April, 2015
Market Authorisation Date: 13 December, 2011
Treatment: Management of postherpetic neuralgia (phn) in adults; Treatment of moderate-to-severe primary restless leg syndrome in adults
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of HORIZANT before it's drug patent expiration?
More Information on Dosage
HORIZANT family patents
